President Donald Trump announced a new tariff plan targeting generic drugs imported into the U.S., set to take effect in stages beginning August 1, 2026. While there will be no tariffs for the first two years, importers will face a 100% levy starting in 2028, followed by a doubling to 200% in 2029. This phased approach is designed to incentivize drug manufacturers to relocate production domestically, with Trump describing the later tariff increases as penalties for companies that fail to establish U.S.-based manufacturing facilities within the grace period.

The move highlights Trump's ongoing strategy to bolster American pharmaceutical production as part of reshoring efforts, a complex and costly challenge given the global nature of supply chains and the reliance on foreign inputs, especially for active pharmaceutical ingredients. Industry experts note that despite the steep tariff escalations, the economics of drug manufacturing might not shift significantly due to high costs and established overseas logistics. For now, tariffs will not impact patented or branded drugs, and prior 100% tariffs on such products imposed earlier this year remain in place.

India, which supplies nearly half of the generic medicines consumed in the U.S. and accounts for roughly a third of its pharmaceutical exports, stands to be highly affected by this tariff policy. Experts warn that while the two-year tariff reprieve provides some relief, the planned tariffs present a significant risk to India's pharmaceutical export sector and trade balance. The ruling may also trigger changes in drug manufacturing and supply strategies, pushing Indian firms to seek exemptions, enhance FDA approvals, and expand into new markets.

With the U.S. election scheduled for 2028, when the first 100% tariff is due to begin, there is speculation that diplomatic negotiations led by New Delhi may delay or alter the implementation of these tariffs. Indian stakeholders are expected to use the two-year window strategically to negotiate tariff relief and bolster investment commitments within the U.S., attempting to safeguard their dominant role in the American generic drug supply amid growing protectionist pressures.